Stocks and Investing Stocks and Investing
Tue, November 10, 2020
Mon, November 9, 2020
Fri, November 6, 2020

Joseph Schwartz Reiterated (BMRN) at Buy with Decreased Target to $108 on, Nov 6th, 2020


Published on 2024-10-27 14:41:25 - WOPRAI
  Print publication without navigation


Joseph Schwartz of SVB Leerink, Reiterated "BioMarin Pharmaceutical Inc." (BMRN) at Buy with Decreased Target from $113 to $108 on, Nov 6th, 2020.

Joseph has made no other calls on BMRN in the last 4 months.



There are 8 other peers that have a rating on BMRN. Out of the 8 peers that are also analyzing BMRN, 6 agree with Joseph's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Matthew Harrison of "Morgan Stanley" Maintained at Hold with Decreased Target to $85 on, Friday, August 21st, 2020
  • Mohit Bansal of "Citigroup" Downgraded from Strong Buy to Hold and Decreased Target to $86 on, Thursday, August 20th, 2020
  • Tim Lugo of "William Blair" Downgraded from Buy to Hold on, Thursday, August 20th, 2020
  • Kennen MacKay of "RBC Capital" Downgraded from Buy to Hold and Decreased Target to $92 on, Thursday, August 20th, 2020
  • Paul Matteis of "Stifel" Downgraded from Strong Buy to Hold and Decreased Target to $100 on, Wednesday, August 19th, 2020
  • George Farmer of "BMO Capital" Maintained at Hold with Increased Target to $108 on, Thursday, August 6th, 2020


These are the ratings of the 2 analyists that currently disagree with Joseph


  • Robyn Karnauskas of "Truist Securities" Maintained at Strong Buy with Decreased Target to $125 on, Thursday, September 10th, 2020
  • Michelle Gilson of "Canaccord Genuity" Maintained at Strong Buy with Decreased Target to $95 on, Thursday, August 20th, 2020